NBIX

156.76

1.77% 2.73

Pre-mercato: 157.50 0.74 +0.47%

Neurocrine Biosciences Inc (NBIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$154.03

Aprire:

$154.31

Volume 24 ore:

878.42K

Relative Volume:

0.70

Capitalizzazione di mercato:

$15.93B

Reddito:

$3.10B

Utile/perdita netta:

$668.60M

Rapporto P/E:

24.10

EPS:

6.5044

Flusso di cassa netto:

$831.30M

1 W Prestazione:

+2.21%

1M Prestazione:

-6.02%

6M Prestazione:

+18.53%

1 anno Prestazione:

+12.29%

Intervallo 1D:

$153.70

$157.03

Intervallo di 1 settimana:

$151.77

$159.40

Portata 52W:

$122.14

$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Nome

Neurocrine Biosciences Inc

Settore

Healthcare (1079)

Industria

Drug Manufacturers - Specialty & Generic (86)

Telefono

(858) 617-7600

Indirizzo

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Dipendente

2,000

Cinguettio

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NBIX Neurocrine Biosciences Inc	156.76	15.55B	3.10B	668.60M	831.30M	6.5044
TAK Takeda Pharmaceutical Co Adr	18.23	57.90B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.07	43.41B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	36.19	42.89B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.25	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	512.70	22.35B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-21	Iniziato	Citigroup	Buy
2025-07-21	Iniziato	Truist	Buy
2025-07-10	Iniziato	Goldman	Buy
2025-04-15	Aggiornamento	Needham	Hold → Buy
2025-04-14	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-29	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-04-24	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-12-13	Ripresa	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Ripresa	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Ripresa	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

Aug 20, 2026

Zacks Investment ResearchGlobes - Globes - Israel Business News

Aug 20, 2026

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance

Aug 20, 2026

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance

Aug 20, 2026

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore

Aug 20, 2026

Aug 18, 2026

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st

Aug 18, 2026

Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus

Aug 16, 2026

S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026

Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026

14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat

Aug 16, 2026

Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st

Aug 16, 2026

Aug 15, 2026

NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Aug 15, 2026

Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 15, 2026

Aug 14, 2026

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals

Aug 14, 2026

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters

Aug 14, 2026

Aug 13, 2026